<p>Galectin Therapeutics（纳斯达克代码：GALT - 获取免费报告）预计将在 2025 年第二季度市场开盘前于 8 月 12 日（星期二）公布其财报。分析师预计该公司本季度每股收益为（$0.16）。</p>
<p>Galectin Therapeutics（纳斯达克代码：GALT - 获取免费报告）上一次发布财报是在 5 月 15 日（星期四）。该公司报告本季度每股收益为（$0.15），超出市场共识预期的（$0.20）$0.05。分析师平均预计 Galectin Therapeutics 在当前财年每股收益为$-1，在下一个财年每股收益也为$-1。</p>
<p>获取 <strong>Galectin Therapeutics</strong> 的提醒：</p>
<h2>Galectin Therapeutics 股价下跌 1.1%</h2>
<p>GALT 股票在周二交易中下跌$0.04，报$3.55。该公司股票交易量为 32,857 股，而其平均交易量为 420,276 股。该公司的 50 日移动平均价格为$2.30，200 日移动平均价格为$1.71。该股票的市值为 2.2469 亿美元，市盈率为-4.93，贝塔值为 0.81。Galectin Therapeutics 的 52 周低点为$0.73，52 周高点为$3.90。</p>
<h2>分析师评级变动</h2>
<p>几位研究分析师对 GALT 股票发表了评论。华尔街 Zen 在 6 月 21 日（星期六）的一份研究报告中将 Galectin Therapeutics 的评级从 “卖出” 上调至 “持有”。HC Wainwright 在 6 月 17 日（星期二）开始对 Galectin Therapeutics 进行覆盖。他们对该股票设定了 “买入” 评级和$6.00 的目标价。</p>
<p><strong>获取我们最新的 GALT 股票报告</strong></p>
<h2>机构资金流入和流出</h2>
<p>一家对冲基金最近增加了对 Galectin Therapeutics 股票的持股。根据该公司最近向证券交易委员会的披露，美国银行（Bank of America Corp DE）在第四季度将其在 Galectin Therapeutics Inc.（纳斯达克代码：GALT - 免费报告）的持股增加了 101.4%。该公司在此期间购买了额外的 19,316 股后，持有 38,358 股。美国银行（Bank of America Corp DE）在最近的报告期末持有约 0.06% 的 Galectin Therapeutics，价值$49,000。目前，11.68% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Galectin Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Galectin Therapeutics Inc 是一家临床阶段的生物制药公司，专注于纤维化、癌症及其他疾病的治疗研究与开发。其主要产品候选药物是 belapectin（GR-MD-02）galectin-3 抑制剂，目前正在进行针对非酒精性脂肪性肝炎（NASH）肝硬化患者预防食管静脉曲张的 2b/3 期临床试验；以及针对肝纤维化、严重皮肤病、黑色素瘤和头颈部鳞状细胞癌的 2 期临床试验。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票比 Galectin Therapeutics 更好</li>
<li>什么是股息竞争者？投资股息竞争者</li>
<li>Figma 的疯狂 IPO 之旅：股票的溢价价格是否合理？</li>
<li>股票股息削减发生，你准备好了吗？</li>
<li>META 获得巨大升级：分析师认为股票可能上涨多高</li>
<li>如何投资科技股以及值得考虑的顶级科技股</li>
<li>诺和诺德股票下跌——但底部是否终于到来？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0FMVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0FMVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Galectin Therapeutics 吗？</h2>
<p>在考虑 Galectin Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Galectin Therapeutics 并不在名单上。</p>
<p>虽然 Galectin Therapeutics 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Galectin治疗

<p>Galectin Therapeutics（纳斯达克代码：GALT）将于 8 月 12 日公布 2025 年第二季度财报，分析师预计每股亏损 0.16 美元。该公司此前报告每股亏损 0.15 美元，超出预期。GALT 股票最近下跌 1.1%，报 3.55 美元，市值为 2.2469 亿美元。机构持股比例为 11.68%。分析师已将 GALT 的评级从 “卖出” 上调至 “持有”，并设定目标价为 6.00 美元。Galectin 专注于纤维化和癌症相关疾病的治疗，其主要产品正在进行临床试验</p>

<p>Galectin Therapeutics (NASDAQ:GALT - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.</p>
<div class="lb-trans"><p>Galectin Therapeutics（纳斯达克代码：GALT - 获取免费报告）预计将在 2025 年第二季度市场开盘前于 8 月 12 日（星期二）公布其财报。分析师预计该公司本季度每股收益为（$0.16）。</p>
</div><p>Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.05. On average, analysts expect Galectin Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Galectin Therapeutics（纳斯达克代码：GALT - 获取免费报告）上一次发布财报是在 5 月 15 日（星期四）。该公司报告本季度每股收益为（$0.15），超出市场共识预期的（$0.20）$0.05。分析师平均预计 Galectin Therapeutics 在当前财年每股收益为$-1，在下一个财年每股收益也为$-1。</p>
</div><p>Get <strong>Galectin Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Galectin Therapeutics</strong> 的提醒：</p>
</div><h2>Galectin Therapeutics Trading Down 1.1%</h2>
<div class="lb-trans"><h2>Galectin Therapeutics 股价下跌 1.1%</h2>
</div><p>GALT stock traded down $0.04 during trading on Tuesday, hitting $3.55. 32,857 shares of the company's stock were exchanged, compared to its average volume of 420,276. The business has a 50-day moving average price of $2.30 and a two-hundred day moving average price of $1.71. The stock has a market capitalization of $224.69 million, a price-to-earnings ratio of -4.93 and a beta of 0.81. Galectin Therapeutics has a 52-week low of $0.73 and a 52-week high of $3.90.</p>
<div class="lb-trans"><p>GALT 股票在周二交易中下跌$0.04，报$3.55。该公司股票交易量为 32,857 股，而其平均交易量为 420,276 股。该公司的 50 日移动平均价格为$2.30，200 日移动平均价格为$1.71。该股票的市值为 2.2469 亿美元，市盈率为-4.93，贝塔值为 0.81。Galectin Therapeutics 的 52 周低点为$0.73，52 周高点为$3.90。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several research analysts have commented on GALT shares. Wall Street Zen raised Galectin Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, June 21st. HC Wainwright started coverage on Galectin Therapeutics in a research report on Tuesday, June 17th. They set a &#34;buy&#34; rating and a $6.00 price target on the stock.</p>
<div class="lb-trans"><p>几位研究分析师对 GALT 股票发表了评论。华尔街 Zen 在 6 月 21 日（星期六）的一份研究报告中将 Galectin Therapeutics 的评级从 “卖出” 上调至 “持有”。HC Wainwright 在 6 月 17 日（星期二）开始对 Galectin Therapeutics 进行覆盖。他们对该股票设定了 “买入” 评级和$6.00 的目标价。</p>
</div><p><strong>Get Our Latest Stock Report on GALT</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 GALT 股票报告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A hedge fund recently raised its stake in Galectin Therapeutics stock. Bank of America Corp DE grew its stake in Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) by 101.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 38,358 shares of the company's stock after purchasing an additional 19,316 shares during the period. Bank of America Corp DE owned approximately 0.06% of Galectin Therapeutics worth $49,000 at the end of the most recent reporting period. 11.68% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一家对冲基金最近增加了对 Galectin Therapeutics 股票的持股。根据该公司最近向证券交易委员会的披露，美国银行（Bank of America Corp DE）在第四季度将其在 Galectin Therapeutics Inc.（纳斯达克代码：GALT - 免费报告）的持股增加了 101.4%。该公司在此期间购买了额外的 19,316 股后，持有 38,358 股。美国银行（Bank of America Corp DE）在最近的报告期末持有约 0.06% 的 Galectin Therapeutics，价值$49,000。目前，11.68% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Galectin Therapeutics</h2>
<div class="lb-trans"><h2>关于 Galectin Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.</p>
<div class="lb-trans"><p>Galectin Therapeutics Inc 是一家临床阶段的生物制药公司，专注于纤维化、癌症及其他疾病的治疗研究与开发。其主要产品候选药物是 belapectin（GR-MD-02）galectin-3 抑制剂，目前正在进行针对非酒精性脂肪性肝炎（NASH）肝硬化患者预防食管静脉曲张的 2b/3 期临床试验；以及针对肝纤维化、严重皮肤病、黑色素瘤和头颈部鳞状细胞癌的 2 期临床试验。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Galectin Therapeutics</li>
<li>What Are Dividend Contenders? Investing in Dividend Contenders</li>
<li>Figma's Wild IPO Ride: Is the Stock's Premium Price Justified?</li>
<li>Stock Dividend Cuts Happen Are You Ready?</li>
<li>META Gets Huge Upgrades: How High Analysts Think Shares Could Go</li>
<li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li>
<li>Novo Nordisk Stock Sinks—But Is a Bottom Finally In?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Galectin Therapeutics 更好</li>
<li>什么是股息竞争者？投资股息竞争者</li>
<li>Figma 的疯狂 IPO 之旅：股票的溢价价格是否合理？</li>
<li>股票股息削减发生，你准备好了吗？</li>
<li>META 获得巨大升级：分析师认为股票可能上涨多高</li>
<li>如何投资科技股以及值得考虑的顶级科技股</li>
<li>诺和诺德股票下跌——但底部是否终于到来？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0FMVA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=GALT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Galectin Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Galectin Therapeutics 吗？</h2>
</div><p>Before you consider Galectin Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Galectin Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Galectin Therapeutics 并不在名单上。</p>
</div><p>While Galectin Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Galectin Therapeutics 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Galectin 治疗公司（GALT）预计将在周二宣布季度财报